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Human cytomegalovirus (HCMV) is the most common congenital infection, and the 25 leading nongenetic cause of sensorineural hearing loss (SNHL) in newborns globally. A 26 gB subunit vaccine administered with adjuvent MF59 (gB/MF59) is the most efficacious 27 tested to-date, achieving 50% efficacy in preventing infection of HCMV-seronegative 28 mothers. We recently discovered that gB/MF59 vaccination elicited primarily non-29 neutralizing antibody responses, that HCMV strains acquired by vaccinees more often 30 included strains with gB genotypes that are distinct from the vaccine antigen, and that 31 protection against HCMV acquisition correlated with ability of vaccine-elicited antibodies 32 to bind to membrane associated gB. Thus, we hypothesized that gB-specific non-33 neutralizing antibody binding breadth and function are dependent on their epitope and 34 genotype specificity as well as their ability to interact with membrane-associated gB. 35
Twenty-four gB-specific monoclonal antibodies (mAbs) isolated from naturally HCMV-36 infected individuals were mapped for gB domain specificity by binding antibody multiplex 37 assay (BAMA) and for genotype preference binding to membrane-associated gB 38 presented on transfected cells. We defined their non-neutralizing functions including 39 seropositive donors, the gB/MF59 vaccine was shown to reduce the magnitude and 115 duration of posttransplant HCMV viremia [11] . gB is a viral fusion protein, essential for 116 viral infection of host cells, and is a target of both neutralizing and non-neutralizing 117 antibodies [12] . Counterintuitively, the gB/MF59 vaccination elicited limited neutralizing 118 responses when compared with HCMV seropositive individuals [13, 14] ; yet, gB/MF59 119 vaccination elicited effector-cell mediated antibody responses, including antibody 120 dependent cellular phagocytosis (ADCP). This observation prompted a hypothesis that 121 non-neutralizing antibodies against gB may contribute to protection against HCMV 122 acquisition [13, 14] . Moreover, effector antibody functions mediated by NK cells may be 123 crucial for targeting HCMV-infected cells, further underlying the significance of non-124 neutralizing antibodies in anti-HCMV immunity [15, 16] . 125 gB is a homotrimeric class III fusion protein that contains 5 defined antigenic 126 domains, namely AD1 -AD5, with AD2 site 1, AD4 (Domain II), and AD5 (Domain I) as 127 the target of neutralizing antibodies, and AD2 site 2, AD1, and the furin cleavage site as 128 reported primary targets of non-neutralizing antibodies [12, 17] . The transmembrane and 129 intravirion domains of gB (AD3), are thought to be obscured from antibody recognition in 130 recently reported that the ability of gB/MF59 vaccine sera to bind to membrane associated 138 gB, via a transfected cell binding assay, predicts risk of HCMV acquisition [19] . 139 Furthermore, like HSV gB and VSV protein G, HCMV gB is undergoes significant 140 conformational transition from prefusion to postfusion states to mediate viral and host-cell 141 membrane fusion [20, 21] . Thus, the CMV vaccine field needs characterization of 142 antibodies that bind distinctly to soluble postfusion gB constructs and cell-associated gB, 143 with the latter possibility representing a distinct prefusion-like structure. 144
Because there are stark differences in the gB epitope binding profiles of naturally-145 infected individuals and gB/MF59 vaccinees [13, 22] , closing the gap in our understanding 146 of immune-protection offered by prior exposure to natural HCMV infection and vaccination 147 will require investigation into how gB as an antigen induces potentially protective effector 148 antibody responses. The aim of this study is to characterize the non-neutralizing gB-149 specific antibody responses in natural HCMV infection for a panel of gB-specific mAbs 150 isolated by memory B cell cultures from three naturally infected individuals [23] . Towards 151 this goal, we analyzed a panel of 24 mAbs by defining their target specificity for gB 152 domains as well as genotype specificity, and analyzed effector functions for these mAbs 153 in ADCC and ADCP assays. Understanding gB diversity, and how gB-specific antibodies 154 bind and mediate antiviral functions across genotypes to different antigenic domains, will 155 be critical if we hope to optimize anti-gB antibody responses in future iterations of a HCMV 156 vaccine. full length gB protein (only missing the transmembrane domain), gB ectodomain, and gB 198 domains were measured as previously described [26] . Carboxylated fluorescent beads 199 (Luminex) were covalently coupled to purified HCMV antigens and incubated with 200 monoclonal antibodies in assay diluent (phosphate-buffered saline, 5% normal goat 201 serum, 0.05% Tween 20, and 1% Blotto milk). The gB domain antigen panel, included full 202 length gB (generously provided by Sanofi), gB ectodomain, gB domain I, gB domain II, 203 gB AD-1 (myBiosource), and biotinylated linear gB AD-2 site 2 (biotin-204 AHSRSGSVQRVTSS), and biotinylated linear gB AD-2 site 1 (biotin-NETIYNTTLKYGD) 205 are previously described [13] . All gB proteins are based on the Towne strain gB (genotype 1). CMV glycoprotein-specific antibody binding was detected with phycoerythrin-207 conjugated goat anti-human IgG (2 µg/mL, Southern Biotech). Beads were washed and 208 acquired on a Bio-Plex 200 instrument (Bio-Rad), and results were expressed as mean 209 fluorescence intensity. A panel CMV seronegative plasma samples (n=30) were included 210 to determine nonspecific baseline levels of binding. Minimal background activity was 211 observed, so the threshold for positivity for each antigen was set at the mean value (100 212 MFI) of negative control sera to each antigen + two standard deviations. Blank beads 213
gB-specific monoclonal antibodies (mAbs
were used in all assays to account for nonspecific binding. All assays included tracking 214 of CMV immunoglobulin (Cytogam, generously gifted by CSL Behring) standard by Levy-215
Jennings charts. The preset assay criteria for sample reporting were coefficient of 216 variation per duplicate values of ≤20% for each sample and ≥100 beads counted per 217 sample. All mAbs were analyzed at a concentration of 30 µg/mL for each antigen: full-218 length gB (gift of Sanofi), gB ectodomain, gB Domain I, gB Domain II, gB AD-1 and gB 219 AD-2 sites 1 and 2. This concentration was predetermined to be within the linear range 220 of binding based on testing serial dilutions of a small subset of gB specific mAbs (1-155, 221 1-235, 2-43, 1-189, 3-54, and 3-74) . 222 223 gB-specific mAb binding strength measured via ELISA. gB-specific monoclonal 224 antibody binding responses were measured against full length gB protein (Sanofi), gB 225 regional epitopes (Ectodomain, Domain I), or gB peptides (AD2 site 1, AD2 site 2). All 226 gB constructs were solubilized in 0.1 M NaHCO3, with proteins plated at a concentration 227 of 3 g/mL and peptides at 10 g/mL respectively. Plates were washed then blocked 228 before adding gB-specific mAbs at either 5 g/mL for conformational protein ELISAs or 100 µg/mL for peptide ELISAs. After incubation with mAbs, plates were washed and 230 incubated with a 1:5000 goat-anti human HRP conjugated IgG secondary (Jackson 231 ImmunoResearch). ELISAs were developed with SeraCare ELISA kit and read at 450 232 nm. 233 234
Assessment of gB-specific mAb avidity via surface plasmon resonance (SPR). 235
Postfusion trimeric gB ectodomain was captured on an NTA sensor chip to ~500 236 response units (RUs) per cycle using a Biacore X100 (GE Healthcare). The chip was 237 doubly regenerated using 0.35 M EDTA and 0.1 M NaOH followed by 0.5 mM NiCl2. 238
Three samples containing only buffer were injected over both ligand and reference flow 239 cells, followed by single injections of each mAb at a concentration of 25 nM. Samples 240 that did not initially result in interpretable sensorgrams were repeated using a 241 concentration of 250 nM. The resulting data were double-reference subtracted and fit to 242 a 1:1 binding model using the Biacore X100 Evaluation software. 243 244 gB genotype-specific transfected cell binding. HEK293T cells were cultured 245 overnight to ~50% confluency in a T25 flask, and then co-transfected using TransIT-246 mRNA Transfection Kit (Mirus Bio) with a GFP-expressing mRNA plasmid (Miltenyi 247 Biotec) and a second plasmid encoding either full length gB from genotypes 1, 2, 3, 4, 248 or 5 (UPenn, Drew Weissman). Transfected cells were incubated at 37℃ and 5% CO2 249 for 24 hours, washed with PBS once, and detached using 0.05% trypsin + EDTA 250 (Thermo Fisher Scientific). Cells were re-suspended in DMEM complete medium and 251 counted using Countess Automated Cell Counter (Invitrogen). 100,000 cells were placed in tubes and stained with LIVE/DEAD Aqua Dead Cell Staining Kit (Thermo 253
Fisher Scientific) diluted 1:1000 at room temperature for 20 minutes. 50,000 live cells 254 were placed in each well of a 96-well V-bottom plate (Corning). The plates were 255 centrifuged at 1,200 x g for 5 minutes and the supernatants were aspirated. Cells were 256 incubated with monoclonal antibodies, which were diluted to 5 g/ml in duplicate in 257 DMEM complete medium, at 37℃ and 5% CO2 for 2 hours. After washing with wash 258 buffer (PBS + 1% FBS) twice, cells were incubated with PE-conjugated mouse anti-259 human IgG Fc (Southern Biotech) diluted 1:200 at 4℃ for 30 minutes. Following two 260 additional wash steps, cells in tubes and plates were resuspended and fixed in PBS + 261 10% formalin for 10 minutes at room temperature. Fixed cells were washed once and 262 resuspended in wash buffer for flow cytometry. Events were acquired on LSR II 263 machine (BD biosciences) using high-throughput sampler (HTS). Data were analyzed 264 with Flowjo software (Tree Star, Inc.), and the PE+ population was identified from the 265 live GFP+ cell population for each sample. Non-specific binding of PE-conjugated 266 mouse anti-human IgG Fc was corrected in the analysis. Mapping the domain-specificity of non-neutralizing gB-specific mAbs from HCMV 346 seropositive individuals 347
We first mapped the binding specificity of the panel of gB-specific mAbs for defined 348 neutralizing and non-neutralizing antigenic domains of gB by BAMA. The most frequent 349 binding specificity was against Domain II (37.5%), as well as AD2 site 2 (12.5%) and 350 AD3/MPER (12.5%) ( Figure 1A) . While 4 mAbs demonstrated detectable binding to 351 both linear AD2 Site 1 and Site 2, these mAbs are likely AD2 Site 2 specific, given that 352 previously described AD2 Site 1 mAbs have neutralizing activity [27, 28] . Interestingly, 353 there were three mAbs, 1-155, 1-237, and 3-18, which bound full length gB, (Sanofi), 354 but did not bind a gB ectodomain that excludes the membrane proximal region (MPER) 355 and the cytodomain containing AD3, suggesting specificity for one of these regions. 356
There are two groups of clonal populations of mAbs found in Individual 1, including 357 mAbs 1-189, 1-190, 1-191, 1-192 which bind full length gB and gB ectodomain 358 conformationally, but not to a defined epitope (termed "conformational" binding), and 359 mAbs 1-223 and 1-224. Antigenic domain-specificity of gB-specific mAbs was 360 heterogenous in Individual 1, but was dominated by Domain II in individuals 2 (57.1%) 361 and 3 (66.7%) ( Figure 1B) . The binding profile for the combined panel of 24 gB-specific 362 mAbs notably excludes any AD1 or AD5 (Domain I) binding mAbs, despite the 363 polyclonal CMV-IgG preparation Cytogam binding to all antigens (data not shown). 364 365 mAb binding kinetics to full length gB and trimeric post-fusion gB ectodomain Next, we sought to describe the binding kinetics of each gB-specific mAb to the full 367 length gB protein vs a trimeric post-fusion gB ectodomain construct. By understanding 368 discrepancies in binding between full length gB and the post-fusion gB ectodomain, we 369 aimed to highlight novel HCMV AD3 or MPER-specific mAbs and their binding kinetics. 370
Multiple mAbs (1-155, 1-189, 1-191, 1-192, 1-237 ) exhibited poor binding strength to 371 post-fusion gB (ectodomain), but retained robust binding to full length gB. MAbs 3-18 372 and 3-58 exhibited poor gB binding to both full length gB and post fusion gB ectodomain 373 (Table 1) . 374
Three isolated gB-specific mAbs with binding to both the linear AD2 Site 1 and 375
Site 2 regions, regardless of individual donor, demonstrated both high binding strength 376
and avidity for full length gB (EC50 0.001 -0.009 g/mL) and gB ectodomain (0.002 -377 0.013 g/mL) (Table 1) . gB mAbs with AD2 site 2 only specificity also had robust 378 binding to full length gB (EC50 0.003 -0.006 g/mL) as well as gB ectodomain (0.004 -379 0.008 g/mL) (Table 1) . Of the mAbs which bound Domain II, all except three, 1-228, 3-380 58 and 3-74, showed strong binding to both full length gB and gB ectodomain (EC50 < 381 0.020 g/mL) (Table 1) . Specifically, mAb 3-74, which binds Domain II predominantly, 382 demonstrated poor binding and avidity to both full length gB and gB ectodomain by 383 ELISA and SPR. Two Domain II-specific mAbs bound with an interesting pattern to gB 384 ectodomain. Domain II-specific mAb 1-228 had strong binding to full length gB (EC50 385 0.001 g/mL) but very poor binding to gB ectodomain by ELISA (EC50 8.014 g/mL) and 386 no detectable (N.D.) avidity by SPR (Table 1) . Further, Domain II-specific mAb 3-58 had 387 poor binding strength to both full length gB (EC50 5.73 g/mL) and gB ectodomain (EC50 MAbs which bound to the full length gB and not the ectodomain in the gB domain 390 mapping, and therefore potentially bind AD3/MPER, 1-155 and 1-237, followed 391 predictable patterns of binding with strong binding to full length gB (EC50 < 0.004 g/mL) 392 and negligible binding strength and avidity to gB ectodomain ( Figure 1A , Table 1 ). mAb 393 3-18, also determined to be AD3/MPER specific by BAMA, demonstrated poor binding 394 measured by both ELISA (EC50 > 100 g/mL) and SPR (KD 22.5 nM) to the ectodomain 395 as well Finally, those mAbs which didn't have a definable epitope specificity by gB 396 domain mapping, and termed "conformational", had highly variable binding strength to 397 gB ectodomain, but fairly strong binding to full length gB. Interestingly, mAb 2-32, which 398 bound both full length gB (EC50 0.003 g/mL) and gB ectodomain (EC50 0.006 g/mL) 399 well via ELISA, as well as has binding detected to both the full length gB and gB 400 ectodomain antigens via BAMA (Figure 1A) , demonstrated undetectable binding to gB 401 ectodomain by SPR (N.D., not detectable). 402 403
Cell associated gB DNA transfected-cell binding 404
We have recently discovered that the magnitude of binding to gB DNA transfected cells 405 is a correlate of protection against primary HCMV acquisition in postpartum and 406 adolescent women vaccinated with gB/MF59 in phase II clinical trials [19] . Next, we 407 investigated whether binding to cell associated gB is dependent upon gB-specific mAb 408 antigenic site specificity. gB-specific mAbs with AD-2 specificity demonstrated high 409 magnitude binding to cell associated gB more consistently than mAbs from any other 410 specificity represented in our panel (Figure 2A ). AD-3 specific mAbs bind poorly to cell 411 associated gB, consistent with epitope location in the transmembrane and cytosolic compartment [12] . Notably, binding to cell associated gB was not correlated to strength 413 of binding to soluble gB measured by ELISA ( Figure 2B ). These findings demonstrate 414 that gB-mAbs of various specificities, except for AD3, are capable of binding cell 415 associated gB with high magnitude. 416
417
Cell associated gB genotype-specific mAb binding 418
We previously reported that gB/MF59 vaccinees may have had reduced acquisition of 419 HCMV strains with gB1 genotype, the genotype matched to the vaccine construct, 420
suggesting strain-specific protection [29] . As such, we next explored how non-421 neutralizing gB-specific mAbs differentially recognize gB genotypes 1-5, as expressed 422 on the surface of a cell. Comparison of total, and genotype specific, gB transfected cell 423 bound populations of each gB-specific mAb ( Figure 3A ) highlights significant variability 424 for cell-associated gB binding across epitope specificities. While a majority of gB-425 specific mAbs bound all 5 genotypes, there was unequal binding magnitude across 426 genotypes for the same mAb. To compare genotype preference amongst gB-specific 427 mAbs ( Figure 3B ), we next assessed the percent representation of each genotype in the 428 sum total gB genotype binding for each mAb. Here, there emerged a clear preference 429 for gB-specific mAbs isolated from these naturally-infected donors for gB genotypes 2 430 and 4, representing the cumulative genotype preference for 11 of 14 gB-specific mAbs 431 with gB genotype specific binding ( Figure 3C ). Genotype-dominant binding was 432 determined by mAbs which bound a single gB genotype with a % PE positive population 433 greater than 5x the % PE positive population of the lowest bound gB genotype. These 434 findings are consistent across epitope specificities. Interestingly, mAbs which were unable to bind gB ectodomain measured by ELISA or BAMA, but bound full length gB 436 and classified as AD3 specific, demonstrated equivalent cell associated gB binding 437 across all tested gB genotypes ( Figure 3A) . These data implicate differences in epitope 438 presentation of soluble gB and cell-associated gB. 439 440
Antibody dependent cellular cytotoxicity (ADCC) 441
Antibody-mediated NK cell cytotoxicity has been demonstrated as a crucial mechanism 442 for controlling HCMV infection [30, 31] . To distinguish the domain specificity of gB-443 specific mAbs which mediate ADCC, we next screened our panel of mAbs for ability to 444 mediate two well defined NK phenotypes of cytotoxic killing, CD107a upregulation, 445
indicative of degranulation, ( Figure 4A ) and CD16 downregulation, indicative of NK cell 446 activation ( Figure 4B) In a study of functional antibody responses to gB/MF59 vaccination, vaccinees were 457
found to demonstrate limited neutralization responses, but robust ADCP [13] . To identify the domain specificity of gB-specific mAbs which can mediate ADCP, we screened our 459 panel of gB-specific mAbs for ability to mediate whole virion phagocytosis ( Figure 5A) . 460
Two gB-specific mAbs, 1-235 and 3-74, mediated phagocytosis of AD169r-GFP virions, 461 which exceeded the baseline ADCP level of non-specific mAbs and seronegative 462 control plasma by 19.4% and 14.7% respectively. To better assess their ADCP potency 463 in both THP-1 cells and primary monocytes isolated from healthy donors ( Figure 5B) , 464 mAbs 1-235 and 3-74 were titrated from a concentration of 100 g/mL. ADCP increased 465 in a dose-dependent manner for 1-235 and 3-74 in both THP1 cells and primary 466 monocytes. Importantly, the gB epitope specificity of ADCP mediating mAb 1-235 was 467 AD2 Site 1 and Site 2, while 3-74 specificity was Domain II ( Figure 1A) . were considered equally protective in a murine cytomegalovirus challenge model [33] . 492 Accordingly, non-neutralizing antibodies which mediate effector functions like ADCP, 493 like those described in this study, may have potential importance as immunological 494 endpoints of a protective HCMV vaccine. 495
A majority (> 90%) of gB-specific antibodies from B cell clones have no 496 neutralizing activity [34] . Indeed, the partially-protective gB/MF59 vaccine elicited limited 497 heterologous neutralization [13] . While the specificity and characteristics of neutralizing 498 gB-specific mAbs have been well described, the types of naturally-elicited gB-specific 499 mAbs that mediate non-neutralizing effector functions which may be critical for 500 protection against HCMV acquisition remain to be fully characterized. 501
In this study, 24 non-neutralizing gB-specific mAbs isolated from naturally 502 HCMV-infected individuals were assessed for epitope binding specificity and affinity, gB 503 genotype preference, and Fc-mediated effector functions. These non-neutralizing mAbs bound predominantly to Domain II, or to one or both of the binding sites of AD2. Domain 505 II is largely the target of neutralizing antibodies, with one study identifying Domain II-506 specific binding by neutralizing antibodies in greater than 90% of HCMV seropositive 507 subjects tested. Interestingly, three mAbs from the panel demonstrated robust binding 508 to the full length gB protein but failed to bind a gB ectodomain, suggesting specificity 509 within the AD3 or MPER region, a portion of the gB construct located in the cytodomain 510 of membrane associated gB [12] . This potentially hidden region on an intact virion or 511 infected cell could certainly be exposed through protein shedding from cell lysis or 512 disruption of the HCMV virion [35] , similarly to other viral structural antigens such as 513 pp150 and pp28. However, it also raises questions regarding the structure of this 514 membrane-associated region of the protein. Interestingly, none of the non-neutralizing 515 gB-specific mAbs in this panel had appreciable binding to AD1 or Domain I. AD1 is 516 targeted by both neutralizing and non-neutralizing mAbs [34, 36] . As such, the lack of 517 Domain I and AD1 binding from this representative panel could be the result of sampling 518 bias from only three individuals [23], by selection bias of excluding mAbs which bind to 519 traditionally neutralizing domains, or non-optimal conformation of the protein used for B 520 cell sorting to isolate these mAbs. 521
Antibodies mediating neutralization after gB/MF59 vaccination and natural 522 infection can be strain specific [13, 37] and may not provide equivalent degrees of 523 protection against all strains. It has been reported that breakthrough HCMV infections in 524 the vaccine subjects receiving gB/MF59, which is a gB genotype 1 based vaccine, were 525 more likely to be infected with HCMV strains expressing gB genotypes 3 or 5 than 526 strains 1, 2, or 4 [29] ; evidence suggesting gB/MF59 induced antibodies were limited due to its strain-specific neutralization or strain-specific antibody effector functions. Our 528 study offers the first evidence that critical gB-specific non-neutralizing antibodies have 529 different strain specific gB recognition when displayed on the surface of a cell. This 530 panel of non-neutralizing gB-specific mAbs generally bound with greater preference to 531 gB genotypes 2 and 4. These findings are in concordance with phylogenetic clustering 532 of the 5 clinically significant HCMV gB genotypes 1/2/4 and 3/5 into two supergroups 533
[29]. The lack of knowledge regarding which HCMV gB genotype or genotypes infected 534 the individuals from which the mAbs were isolated limits the assertions we can make 535 about how gB genotype specific antibodies may be raised by natural infection. Clinically, 536
prevalence of HCMV gB variants may be influenced by geography, immune status, and 537
prior infection with HCMV of other gB variants [38] [39] [40] . Future efforts might address the 538 question of gB variant specific non-neutralizing recognition and antibody function by 539 utilizing mAbs isolated from individuals that have been tested for endogenous viral 540 strains or have known exposure to a specific gB genotype variant. 541 A notable finding from studying full-length gB-binding mAbs that may be AD3-or 542 MPER-specific, is their breadth of membrane associated gB binding. These mAbs, 1-543 155, 1-237, and 3-18 demonstrate negligible gB ectodomain and postfusion gB trimer 544 binding by both ELISA and SPR yet yield comparable signals for transfected cell binding 545 to other gB ectodomain binding mAbs. With AD3 thought to be buried in the cytodomain 546
[12], these findings raise the question: how do presentation of gB epitopes differ as a 547 soluble protein versus a membrane-associated protein? As a viral fusogen, gB is 548 thought to undergo transformation from a prefusion conformation to a postfusion 549 conformation to facilitate entry into a host cell [21, 41] . While this study does not define a specific prefusion structure, it does highlight how a distinct prefusion-like gB on a cell 551 surface may expose different epitopes than soluble postfusion gB, potentially 552 accounting for improved membrane associated gB binding of AD3-specific mAbs. 553
Notably, it was recently reported that the ability of gB/MF59 vaccine sera to bind to gB 554 transfected cells predicts risk of HCMV acquisition [19] . Taken together, these findings 555 warrant further investigation of gB conformation-specific antibody binding, to parse out 556 the epitope binding specificity and effector functions of gB vaccine-elicited Abs. 557
This study demonstrates the first effort to identify gB domain specificity and 558 function of antibodies that mediate Fc receptor functions like ADCP and ADCC elicited 559 by natural HCMV infection. While little is known about gB-specific non-neutralizing 560 functions in naturally-infected individuals, investigations of gB/MF59 vaccinees has 561
shown this class of antibody may indeed be a desirable target of vaccines that aim to 562 protect against primary HCMV acquisition [13] . It is now evident that non-neutralizing 563
Abs are not limited to traditional "non-neutralizing" epitopes [12, 17] . Even more, these 564 mAbs, while preferentially binding to certain gB genotypes, retain the ability to bind 565 across a spectrum of gB genotype variants. Ultimately this work contributes to the field 566 of HCMV vaccinology by emphasizing the impact of epitope binding specificity, binding 567 strength, and genotype breadth amongst functional non-neutralizing gB-specific mAbs. 568
By improving our knowledge of gB immunogenicity elicited by natural infection, and the 569 specificity of antibody responses that may mediate key functions other than traditional 570 neutralization, this work informs rational design of new HCMV vaccines that aim to 571 reduce the devastating burden of HCMV disease in both congenital infection and 572 transplant settings. 5 1 -2 3 7  3 -1 8 1 -1 8 9 1 -1 9 0 1 -1 9 1 1 -1 9 2 1 -2 
